Hangzhou Tigermed Consulting 

$4.45
2
+$0.45+11.25% Monday 20:00

統計

當日最高
4.2
當日最低
4.2
52週高點
4.45
52週低點
4
成交量
612
平均成交量
0
市值
3.83B
本益比
34.23
股息殖利率
0.41%
股息
0.02

即將到來

股息

0.41%股息殖利率
Aug 26
$0.02
Aug 25
$0.04
Aug 24
$0.08
Jul 23
$0.08
10年成長
不適用
5年成長
不適用
3年成長
-19.3%
1年成長
不適用

財報

29Aug預期
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
下一步
0.07
0.31
0.56
0.81
預期EPS
0.26721852928254
實際EPS
不適用

財務

13.21%利潤率
有盈利
2020
2021
2022
2023
2024
2025
936.7M營收
123.76M淨利

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
Show more...
執行長
Dr. Xiaoping Ye D.Phil, EMBA, M.D., Ph.D.
員工
11130
國家
美國
ISIN
US41044T1088

上市

0 Comments

分享你的想法

FAQ

Hangzhou Tigermed Consulting 今天的股價是多少?
HNGZY 目前價格為 $4.45 USD,過去 24 小時上漲了 +11.25%。在圖表上更密切關注 Hangzhou Tigermed Consulting 股價表現。
Hangzhou Tigermed Consulting 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 OTC Link 交易所,Hangzhou Tigermed Consulting 的股票以代號 HNGZY 進行交易。
Hangzhou Tigermed Consulting 的股價在上漲嗎?
HNGZY 股票較上週上漲 +0%,本月上漲 +11.25%,過去一年 Hangzhou Tigermed Consulting 上漲 +11.25%。
Hangzhou Tigermed Consulting 的市值是多少?
今天 Hangzhou Tigermed Consulting 的市值為 3.83B
Hangzhou Tigermed Consulting 下一次財報日期是什麼時候?
Hangzhou Tigermed Consulting 將於 August 29, 2026 公布下一次財報。
Hangzhou Tigermed Consulting 上一季度的財報如何?
HNGZY 上一季度的財報為每股 0.01 USD,預估為 0.04 USD,帶來 -77.21% 的驚喜。下一季度的預估財報為每股 不適用 USD。
Hangzhou Tigermed Consulting 去年的營收是多少?
Hangzhou Tigermed Consulting 去年的營收為 936.7MUSD。
Hangzhou Tigermed Consulting 去年的淨利是多少?
HNGZY 去年的淨收益為 123.76MUSD。
Hangzhou Tigermed Consulting 會發放股息嗎?
是的,HNGZY 的股息每 年度 發放一次。每股最新股息為 0.04 USD。截至今日,股息殖利率(FWD)% 為 0.41%。
Hangzhou Tigermed Consulting 有多少名員工?
截至 July 16, 2026,公司共有 11,130 名員工。
Hangzhou Tigermed Consulting 位於哪個產業?
Hangzhou Tigermed Consulting從事於Health & Wellness產業。
Hangzhou Tigermed Consulting 何時完成拆股?
Hangzhou Tigermed Consulting 最近沒有進行任何拆股。
Hangzhou Tigermed Consulting 的總部在哪裡?
Hangzhou Tigermed Consulting 的總部位於 美國 的 Hangzhou。